BE704075A - - Google Patents
Info
- Publication number
- BE704075A BE704075A BE704075DA BE704075A BE 704075 A BE704075 A BE 704075A BE 704075D A BE704075D A BE 704075DA BE 704075 A BE704075 A BE 704075A
- Authority
- BE
- Belgium
- Prior art keywords
- derivative
- fluorescein
- hydrogen
- group
- substituents
- Prior art date
Links
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 36
- 229910052753 mercury Inorganic materials 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 23
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 230000002285 radioactive effect Effects 0.000 claims description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960001483 eosin Drugs 0.000 description 2
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- SQFDQLBYJKFDDO-UHFFFAOYSA-K merbromin Chemical compound [Na+].[Na+].C=12C=C(Br)C(=O)C=C2OC=2C([Hg]O)=C([O-])C(Br)=CC=2C=1C1=CC=CC=C1C([O-])=O SQFDQLBYJKFDDO-UHFFFAOYSA-K 0.000 description 2
- 229940008716 mercurochrome Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000003699 striated muscle Anatomy 0.000 description 2
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000002314 autoradiolysis reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- -1 neohydrin Chemical compound 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE704075 | 1967-09-20 | ||
| NL6713162A NL6713162A (enrdf_load_stackoverflow) | 1967-07-12 | 1967-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE704075A true BE704075A (enrdf_load_stackoverflow) | 1968-02-01 |
Family
ID=25656614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE704075D BE704075A (enrdf_load_stackoverflow) | 1967-09-20 | 1967-09-20 |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE704075A (enrdf_load_stackoverflow) |
-
1967
- 1967-09-20 BE BE704075D patent/BE704075A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2460672A1 (fr) | Preparation de poudre d'acetylsalicylate pour injection | |
| Hopkins | A contribution to the chemistry of pterins | |
| BE1001527A6 (fr) | Preparation aqueuse stabilisee d'acide folique. | |
| BE704075A (enrdf_load_stackoverflow) | ||
| FR2505834A1 (fr) | Derives de la thiazolidine | |
| FR2482458A1 (fr) | Compositions antitumorales a base de methanesulfon-m-anisidine | |
| DE1668887A1 (de) | Calciumthioctat | |
| LU85296A1 (fr) | Procede de preparation de derives de pyrimidinetrione | |
| BE897980A (fr) | Procede pour la preparation d'une solution a usage pharmaceutique contenant un nouveau complexe mixte polynuclaire de fer (iii) comme ingredient actif | |
| EP0034521B1 (fr) | Médicament analgésique contenant de la 1-(3'benzofuryl)-4-benzylpipérazine et son procédé de préparation | |
| CH648302A5 (fr) | Lactates du 4'-(9-acridinylamino-methanesulf-m-anidiside, leur procede de production et composition pharmaceutique les contenant. | |
| FR2587214A1 (fr) | Anticoagulants constitues d'heteropolyanions tungstiques et utilisation de ces heteropolyanions a la preparation de medicaments anticoagulants | |
| Schatz et al. | Iodinated phenylalanines. Tests for selective localization in pancreas and preparation of 3, 4, 5-triiodophenylalanine | |
| EP0210091B1 (fr) | Procédé nouveau de réduction du pertechnétate | |
| BE887220A (fr) | Compositions antitumeurs | |
| EP0209511A1 (fr) | Chlorhydrates de chlorures de dérivés d'aminoalkyl-2 hydroxy-9 ellipticinium et compositions pharmaceutiques en contenant | |
| LU83081A1 (fr) | Compositions antitumeurs | |
| DE828102C (de) | Verfahren zur Herstellung von 3-Phenaceturyl-5-dimethyl-thiazolidin-4-carbonsaeure | |
| US3154469A (en) | Method of increasing potassium levels by administering potassium salts of ethylene-1:2-dicarboxylic acid | |
| DE2210382C2 (de) | 10-(ω-[N-Diazabicyclo-alkyl]-acyl)-phenothiazine, ihre Säureadditionssalze, Verfahren zu ihrer Herstellung und Arzneimittel | |
| US768561A (en) | Antiseptic compound. | |
| Wright | XXII.—Isomeric terpenes and their derivatives. Part I | |
| CH440319A (fr) | Procédé pour la fabrication de composés solubles de dérivés nitrofuraniques | |
| BE400671A (enrdf_load_stackoverflow) | ||
| BE717932A (enrdf_load_stackoverflow) |